http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017336250-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_91e2053d826908ef154d84857e5aa47d
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-29
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-593
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P5-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P7-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-50
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-60
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P5-18
filingDate 2017-09-28-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0f8a8cd400c443811772d2bd7e9a2115
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6058572f5a8fad1a916848ab2b1d1672
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_de8aff9abe941d5e95afe3e519d9a0d9
publicationDate 2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2017336250-A1
titleOfInvention Incremental dose finding in controlled-release PTH compounds
abstract The present invention relates to pharmaceutical compositions comprising a controlled-release PTH compound or a pharmaceutically acceptable salt, hydrate, or solvate thereof, for use in a method of treating, controlling, delaying or preventing a condition which can be treated, controlled, delayed or prevented with PTH, wherein the pharmaceutical composition comprising the controlled-release PTH compound is administered in accordance with a dosage regimen in which dose adjustment in response to hypocalcemia or hypercalcemia is performed in increments of no more than 25%.
priorityDate 2016-09-29-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID465635670
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID153263064
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466304158
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466740117
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID163893587
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468090043
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425938550
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467785653

Total number of triples: 38.